Carregant...
Adherence to BCR-ABL Inhibitors: Issues for CML Therapy
Treatment for chronic myeloid leukemia (CML) has improved substantially in the last 20 years, especially since the introduction of oral BCR-ABL inhibitors a decade ago. However, for patients to reap the benefits of BCR-ABL inhibitors, they must likely be on therapy for the remainder of their lives....
Guardat en:
| Publicat a: | Clin Lymphoma Myeloma Leuk |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4428159/ https://ncbi.nlm.nih.gov/pubmed/22633166 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2012.04.002 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|